1009 related articles for article (PubMed ID: 21138825)
1. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
2. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
[No Abstract] [Full Text] [Related]
4. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
5. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
6. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
9. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
10. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
13. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
Liutkus J; Rosas Guzman J; Norwood P; Pop L; Northrup J; Cao D; Trautmann M
Diabetes Obes Metab; 2010 Dec; 12(12):1058-65. PubMed ID: 20977576
[TBL] [Abstract][Full Text] [Related]
15. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Ratner RE; Han J; Kim DD; Fineman MS; Baron AD
Diabetes Care; 2005 May; 28(5):1092-100. PubMed ID: 15855572
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D; Cuddihy RM; Hanefeld M; Kumar A; González JG; Chan M; Wolka AM; Boardman MK;
Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
19. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
[TBL] [Abstract][Full Text] [Related]
20. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]